HAYA Therapeutics has enrolled the first cohort in a Phase 1a/b trial of HTX-001, an antisense oligonucleotide targeting WISPER, a stress-responsive RNA in the heart. Preclinical data show the approach reduces cardiac fibrosis and improves function in nonobstructive hypertrophic cardiomyopathy, a genetic disorder that stiffens the heart muscle and impairs its ability to relax and pump effectively.
Key Points
- HTX-001 targets WISPER RNA to reprogram cardiac fibroblasts and reduce pathological fibrosis
- Phase 1a/b trial enrolling healthy volunteers and nHCM patients across dose cohorts
- Preclinical studies demonstrate improved cardiac function and reduced scar tissue formation
Longevity Analysis
This trial addresses a fundamental constraint on cardiovascular aging: the progressive stiffening and scarring of heart tissue that impairs contractility and diastolic function. By targeting the molecular signals that drive cardiac fibroblast activation and fibrosis, HTX-001 operates upstream of structural damage—potentially interrupting the cascade that leads to reduced cardiac output and increased mortality risk. The approach reflects a shift toward cell-state reprogramming rather than symptom management, which could extend both functional lifespan and quality of life in populations with genetic cardiomyopathies and age-related cardiac decline.
Original published by Longevity.Technology.